|
Trial Name |
Description of Trial |
CHI-SQUARE |
Rimonabant 20 mg OD (once daily) for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors. |
CLEAR HARMONY |
A randomized, double-blind, placebo-controlled, multicenter long-term safety and tolerability study of ETC-1002 in patients with hyperlipidemia at high cardiovascular risk who are not adequately controlled by their lipid-modifying therapy. Can HDL infusions significantly quicken atherosclerosis regression? Infusions plus IVUS. |
CLEAR SYNERGY OASIS-9 |
A 2x2 factorial randomized controlled trial of CoLchicine and spironolactonE in patients with myocARdial infarction/SYNERGY Stent Registry- Organization to Assess Strategies for Ischemic Syndromes 9. |
COAPT |
Canadian Observational Anti-Platelet Study (COAPT): |
COLCOT |
Colchicine cardiovascular outcomes trial.This study is to determine if a long-term treatment with colchicine, a drug that has anti-inflammatory effects, reduces the recurrence rate of cardiovascular events in patients with MI. |
COMPASS |
A randomized controlled trial of rivaroxaban for the prevention of major cardiovascular events in patients with coronary or peripheral artery disease. Cardiovascular outcomes for people using anticoagulation strategies (Long Term Open-Label). |
COMPLETE |
A randomized, comparative effectiveness study of complete versus culprit-only revascularization strategies to treat multi-vessel disease after primary percutaneous coronary intervention for ST-segment elevation myocardial infarction (STEMI). |
|
COPERNICUS |
Placebo-controlled study to determine the effect of carvedilol on mortality in patients with severe chronic heart failure. |
CRESCENDO |
Rimonabant 20 mg OD (once daily) for reducing the risk of major cardiovascular events in abdominally obese patients with clustering risk factors. |
|
C-SIRIUS |
A canadian multicenter, randomized, double-blind study of the siolimus-coated Bx velocityTM balloon-expandable stent in the treatment of patients with de novo coronary artery lesions. |
CURRENT/OASIS 7 |
Comparison of a high loading dose regimen of clopidogrel versus standard dose in patients with unstable angina or non-ST segment elevation myocardial infarction managed with an early invasive strategy. |
|
CVT 3037 |
A double-blind, randomized, placebo-controlled, parallel-group study of ranolazine SR at a dose of 1000 mg twice a day in patients with chronic angina who remain symptomatic despite treatment with amlodipine 10 mg once a day. |
DABI-PTS |
The prevalence of post-thrombotic syndrome (PTS) in DVT patients treated with dabigatran a cross sectional assessment of Re-cover Study patients. |
DAL-GENE |
A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent acute coronary syndrome. |
DAL-PLAQUE 2 |
A phase III, multi-center, double-blind, randomized, placebo-controlled study, evaluating the effect of treatment with dalcetrapib 600 mg on atherosclerotic disease as measured by I. Coronary intravascular ultrasoud (IVUS) and quantitative coronary angiography II. Carotid B-Mode ultrasound intima media thickness (IMT) and total plaque volume in subjects undergoing coronary angiography who have coronary artery disease. |
DAPA-ACT HF-TIMI 68 |
A Multicenter, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Trial to Evaluate the Effect of In-Hospital Initiation of Dapagliflozin on Clinical Outcomes in Patients with Heart Failure with Reduced Ejection Fraction Who Have Been Stabilized During Hospitalization for Acute Heart Failure (Protocol No. D1690C00078) |
|
DISCOVERY |
Direct statin comparison of LDL-C values: an evaluation of rosuvastatin therapy. |
|
DISTINCT |
Biodivysio™ stent to demonstrate the equivalency to the ACS duet concerning the 6-month target vessel failure (TVF) rate. |
DREAM-HF |
A double-blind, randomized, sham-procedure controlled, parallel-group efficacy and safety study of allogeneic mesenchymal precursor cells (rexlemestrocel-L) in patients with chronic heart failure due to left ventricular systolic dysfunction of either ischemic or nonischemic etiology. |
e-BMX |
A canadian pre-market registry of BioMatrixk FlexTM drug eluting stents. |
EINSTEIN-CHOICE |
Reduced-dose rivaroxabanand standard-dose rivaroxaban versus ASA long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism. |
|
ELITE-III |
A captopril-controlled study to evaluate the effects of losartan on mortality in patients with symptomatic heart failure. |
| EMPACT-MI | EMPAgliflozin for the prevention of Chronic heart failure and morTality after an acute Myocardial Infarction. EMPACT-MI. |
EMPEROR-PRESERVED |
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with preserved ejection fraction (HFpEF). |
EMPEROR - REDUCED |
A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced ejection fraction (HFpEF). |
EMPULSE |
A multicentre, randomised, double-blind, 90-day superiority trial to evaluate the effect on clinical beneft, safety and tolerability of once daily oral EMPagliflozin 10 mg compared to placebo, initiated in patients hospitalised for acUte heart faiLure (de novo or decompensated chronic HF) who have been StabilisEd (EMPULSE). |
|
ESCALAT |
Efegatran and streptokinase to canalize arteries like accelerated t-PA for patients with acute myocardial Infarction. |
|
ESSENCE |
Efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q myocardial infarction. |
|
ESSENTIAL |
The studies of oral enoximone therapy in advanced heart failure, a phase III, randomized, double-blind, multicenter, parallel group, placebo-controlled study of oral enoximone vs. placebo in advanced chronic heart failure subjects. |
EVEREST |
A multi-centre, randomized, double-blind, placebo-controlled study to evaluate the long term efficacy and safety of oral tolvaptan tablets in subjects hospitalized with worsening CHF. |
| EVEREST II I | A phase II prospective, multi-center, randomized study of the Evalve Inc., Cadiovascular Valve Repair System (CVRS) in the treatment of mitral valve regurgitation. |
|
EXCITE |
Evaluation of oral xemilofiban in controlling thrombolytic events. |
| EXAMINE | Double-blind, placebo controlled study to evaluate CV outcomes following teatment with Alogliptin in addition ot standard of care with type 2 diabetes and ACS. |
|
EXPEDITION |
A double-blind, placebo-controlled, multinational trial to investigate the effect of IV treatment with the Na+/H+ exchange inhibitor cariporide (HOE642) on all-cause mortality and non-fatal myocardial infarction in patients at risk of myocardial necrosis during and after coronary artery bypass graft surgery. |
|
EZETIMBE |
A randomized, double-blind, placebo-controlled, multicenter study to evaluate, efficacy, safety, and tolerability of Ezetimibe 10 mg or placebo co-administered with existing atorvastatin 10 mg or 20 mg in attaining low-density lipoprotein cholesterol target levels in patients with hypercholesterolemia and coronary heart disease. |
| FREEDOM | Future revascularization evaluation in patients with diabetes mellitus: Optimal management of multi-vessel disease. |
| GALILEO | Global, multicenter, open-label, randomized, event-driven, active-controlled study comparing a rivaroxaban-based antithrombotic strategy to an antiplatelet-based strategy after transcatheter aortic valve replacement to optimize clinical outcomes. |
| G-CHF | A global registry to study the demographics, socioeconomic and clinical factors, etiologies, pathophysiology, management, barriers to care, and outcomes of heart failure. |
GEMINI ACS I I |
A randomized, double-blind, double-dummy, active-controlled, parallel-group, multicenter study tocompare the safety of rivaroxaban versus acetylasalicylic acid in addition to either clopidogrel or ticagrelor therapy in subjects with acute coronary syndrome. |
GLAGOV |
A randomized, multicenter, placebo-controlled, parallel group study to determine the effect of AMG145 treatment on athersclerotic disease burden as measured by intravascular ultrasound in subjects undergoing coronary catheterization. |
GLAGOV OLE |
A multicenter, open-label extension (OLE) study to assess the long-term safety and efficacy of evolocumab. |
|
GUARDIAN |
Guard during ischemia against necrosis. Investigating the effect of Na+/H+ exchanged inhibitor HOE642A (cariporide). |
 |
 |
©Victoria Heart Institute Foundation
"Yesterday's research is tomorrow's best practice... Today's research leads to tomorrow's breakthroughs."